2024 IATDMCT立场声明：英夫利西单抗治疗药物监测最佳实践

2024-04-17 国际治疗药物监测和临床毒性协会 Ther Drug Monit 发表于上海

本文主要审查了英夫利昔单抗在IMIDs患者中的治疗性药物监测(TDM)的现有数据，并提供了在当前临床实践中实施TDM的实用指南。

中文标题：

英文标题：

Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology

发布机构：

国际治疗药物监测和临床毒性协会

发布日期：

2024-04-17

简要介绍：

英夫利昔单抗是一种抗肿瘤坏死因子单克隆抗体，改变了免疫介导的炎症性疾病（IMIDs）的药物治疗。本文主要审查了英夫利昔单抗在IMIDs患者中的治疗性药物监测(TDM)的现有数据，并提供了在当前临床实践中实施TDM的实用指南。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=aa3fe1c003e092cb, title=2024 IATDMCT立场声明：英夫利西单抗治疗药物监测最佳实践, enTitle=Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology, guiderFrom=Ther Drug Monit, authorId=0, author=, summary=本文主要审查了英夫利昔单抗在IMIDs患者中的治疗性药物监测(TDM)的现有数据，并提供了在当前临床实践中实施TDM的实用指南。, cover=https://img.medsci.cn/Random/medical-conference-P42ZDP5.jpg, journalId=0, articlesId=null, associationId=1995, associationName=国际治疗药物监测和临床毒性协会, associationIntro=国际治疗药物监测和临床毒性协会(IATDMCT,International Association of Therapeutic Drug Monitoring and Clinical Toxicity), copyright=0, guiderPublishedTime=Wed Apr 17 00:00:00 CST 2024, originalUrl=, linkOutUrl=, content=<div class="guideDetailsCont flex-row-between-start" style="color: #333333;"> <div class="detailsContRight" style="color: #222222;">英夫利昔单抗是一种抗肿瘤坏死因子单克隆抗体，改变了免疫介导的炎症性疾病（IMIDs）的药物治疗。本文主要审查了英夫利昔单抗在IMIDs患者中的治疗性药物监测(TDM)的现有数据，并提供了在当前临床实践中实施TDM的实用指南。</div> </div>, tagList=[TagDto(tagId=11226, tagName=英夫利西单抗)], categoryList=[CategoryDto(categoryId=15, categoryName=风湿免疫, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100)], articleKeywordId=11226, articleKeyword=英夫利西单抗, articleKeywordNum=6, guiderKeywordId=11226, guiderKeyword=英夫利西单抗, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=618, appHits=23, showAppHits=0, pcHits=11, showPcHits=595, likes=0, shares=9, comments=0, approvalStatus=1, publishedTime=Fri Apr 26 20:03:00 CST 2024, publishedTimeString=2024-04-17, pcVisible=1, appVisible=1, editorId=0, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=dajiong, createdTime=Wed Apr 24 16:20:44 CST 2024, updatedBy=8538692, updatedName=梅斯话题小助手, updatedTime=Wed Apr 24 19:19:48 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=上海, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2024 IATDMCT立场声明：英夫利西单抗治疗药物监测最佳实践.pdf)])